2018
Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Drugs T, Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Traore A, Diallo N, Diakite H, Togo A, Koumare S, Keita M, Camara D, Somé A, Coulibaly A, Traore O, Dama S, Goita S, Djimde M, Bamadio A, Dara N, Maiga H, Sidibe B, Dao F, Coulibaly M, Alhousseini M, Niangaly H, Sangare B, Diarra M, Coumare S, Kabore M, Ouattara S, Barry A, Kargougou D, Diarra A, Henry N, Soré H, Bougouma E, Thera I, Compaore Y, Sutherland C, Sylla M, Nikiema F, Diallo M, Dicko A, Picot S, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Gil J, Björkman A, Ouedraogo J, Sirima S, Djimde A. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet 2018, 391: 1378-1390. PMID: 29606364, PMCID: PMC5889791, DOI: 10.1016/s0140-6736(18)30291-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyFirst-line artemisinin-based combination therapyArtemether-lumefantrineDay 28Day 42Study drugUncomplicated malariaMalaria episodesEligible participantsIncidence ratePan African Clinical Trials RegistryUncomplicated P falciparum malariaCurrent first-line therapyAfrican Clinical Trials RegistryDeveloping Countries Clinical Trials PartnershipDihydroartemisinin-piperaquine treatmentFirst malaria episodeP falciparum malariaUncomplicated malaria episodesFirst-line therapyHistory of feverClinical Trials RegistryNon-falciparum speciesMild transient elevationUK Medical Research Council
2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilities
2013
Clinical signs and symptoms cannot reliably predict Plasmodium falciparum malaria infection in pregnant women living in an area of high seasonal transmission
Tahita M, Tinto H, Menten J, Ouedraogo J, Guiguemde R, van Geertruyden J, Erhart A, D’Alessandro U. Clinical signs and symptoms cannot reliably predict Plasmodium falciparum malaria infection in pregnant women living in an area of high seasonal transmission. Malaria Journal 2013, 12: 464. PMID: 24373481, PMCID: PMC3877878, DOI: 10.1186/1475-2875-12-464.Peer-Reviewed Original ResearchConceptsPregnant womenMalaria infectionRapid diagnostic testsCommon signsPredictive valuePlasmodium falciparum malaria infectionMajor public health problemDiagnostic testsCommon malaria symptomsHigh seasonal transmissionFalciparum malaria infectionHistory of feverSymptoms of malariaPublic health problemPositive predictive valueIntensity of transmissionClinical malariaClinical presentationGestational ageMalaria symptomsDistrict hospitalOverall prevalenceMaternity clinicsClinical signsEndemic countries
2012
An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso
Valea I, Tinto H, Drabo M, Huybregts L, Sorgho H, Ouedraogo J, Guiguemde R, van Geertruyden J, Kolsteren P, D'Alessandro U, the FSP/MISAME study Group. An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malaria Journal 2012, 11: 71. PMID: 22433778, PMCID: PMC3338396, DOI: 10.1186/1475-2875-11-71.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemiaAntimalarialsBurkina FasoDrug Administration ScheduleDrug CombinationsFemaleHumansInfant, Low Birth WeightInfant, NewbornMalaria, FalciparumPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPregnancy TrimestersProspective StudiesPyrimethamineRiskSulfadoxineTime FactorsYoung AdultConceptsLow birth weightFirst malaria infectionDoses of SPMalaria infectionBirth weightPerinatal mortalityMaternal anemiaFirst trimesterPregnant womenHigh riskBackgroundA prospective studyIntermittent preventive treatmentAntenatal care visitsHistory of feverIncidence rate ratiosCare visitsThird doseMethodsStudy participantsProspective studySecond trimesterPreventive treatmentHealth centersHealth facilitiesPregnancyInsecticidal nets